BAFF-R CAR-T
/ Hebei Taihe Chunyu Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2026
Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
(clinicaltrials.gov)
- P1/2 | N=20 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2
1 to 1
Of
1
Go to page
1